ipratropium

(redirected from Atrovent HFA)
Also found in: Dictionary.

Related to Atrovent HFA: Symbicort, Ventolin HFA

ipratropium

[ip-rah-tro´pe-um]

an anticholinergic and antimuscarinic, used in the form of the bromide salt as an aerosol bronchodilator in treatment of bronchospasm and as a nasal spray for the relief of rhinorrhea.

i·pra·tro·pi·um

(i'pră-trō'pē-ŭm),

A synthetic quaternary ammonium compound, chemically related to atropine, that has anticholinergic activity and is a bronchodilator given by inhalation.

ipratropium

(ĭp′rə-trō′pē-əm)

An inhalant bronchodilator drug, C₂₀H₃₀NO₃, used in the form of its bromide to treat obstructive pulmonary disease.

Mentioned in ?

References in periodicals archive ?

* Special Considerations: Atrovent HFA is not indicated for initial treatment of acute bronchospasm where a rapid response is required.

Kelleher has no financial affiliation with Atrovent HFA or Boehringer Ingelheim.

Atrovent HFA Inhalation Aerosol, Evoclin Foam

Atrovent HFA Inhalation Aerosol is for patients 12 years and older.

In clinical trials, the most common adverse events related to Atrovent HFA were dry mouth and taste perversion (bitter taste), each occurring in fewer than 2% of participants.

New bronchodilator joins group of environmentally friendly agents

The FDA approved ipratropium bromide HFA (Atrovent HFA Inhalation Aerosol), a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema in patients 12 years and older.